<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02836600</url>
  </required_header>
  <id_info>
    <org_study_id>16191</org_study_id>
    <secondary_id>I6F-JE-JJCC</secondary_id>
    <nct_id>NCT02836600</nct_id>
  </id_info>
  <brief_title>A Study of LY3039478 in Japanese Participants With Advanced Solid Tumors</brief_title>
  <official_title>A Phase 1 Study of LY3039478 in Japanese Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the tolerability of the study drug LY3039478 in&#xD;
      Japanese participants with advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 9, 2016</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Actual">July 5, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with LY3039478 Dose-Limiting Toxicities (DLTs)</measure>
    <time_frame>Cycle 1 (28 days)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3039478</measure>
    <time_frame>Cycle 1 Day 1 through Cycle 2 Day 1 (28 day cycles)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Area Under the Curve (AUC) of LY3039478</measure>
    <time_frame>Cycle 1 Day 1 through Cycle 2 Day 1 (28 day cycles)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR): Percentage of Participants Who Achieve Complete Response (CR) or Partial Response (PR)</measure>
    <time_frame>Baseline through Disease Progression or Death (estimated at up to 9 months)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <arm_group>
    <arm_group_label>LY3039478</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3039478 given orally TIW (3 times per week) in 28 day cycles. Treatment will continue until disease progression, development of unacceptable toxicity, or any other discontinuation criteria are met.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3039478</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>LY3039478</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological or cytological evidence of a diagnosis of solid tumor that is advanced&#xD;
             and/or metastatic.&#xD;
&#xD;
          -  In the judgment of the investigator, participants must be appropriate candidates for&#xD;
             experimental therapy after available standard therapies have failed or for whom&#xD;
             standard therapy is not appropriate.&#xD;
&#xD;
          -  Performance status of ≤1 on the Eastern Cooperative Oncology Group (ECOG) scale.&#xD;
&#xD;
          -  Adequate organ function, including hematologic, hepatic, and renal.&#xD;
&#xD;
          -  Estimated life expectancy of ≥12 weeks.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Received previous therapy for cancer within 14 or 21 days of the initial dose of study&#xD;
             drug for a nonmyelosuppressive or myelosuppressive agents, respectively.&#xD;
&#xD;
          -  Have serious preexisting medical conditions.&#xD;
&#xD;
          -  Have current or recent (within 3 months of study drug administration) gastrointestinal&#xD;
             disease with chronic or intermittent diarrhea.&#xD;
&#xD;
          -  Have an active bacterial, fungal, and/or known viral infection.&#xD;
&#xD;
          -  Have known acute or chronic leukemia or current hematologic malignancies that may&#xD;
             affect the interpretation of results.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <zip>277 8577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 15, 2016</study_first_submitted>
  <study_first_submitted_qc>July 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2016</study_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>notch inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

